Search

Background The resistance related with production of extended-spectrum beta-lactamase (ESBL) is an important problem that we face when we are treating infections caused by enterobacteriaceae. We aimed to evaluate the frequency of ESBL production in E. coli strains and the rate of antibiotic resistance isolated from in our microbiology laboratory. Method E. coli strains isolated from various clinical specimens between January 2010 – December 2011 were assessed retrospectively. Resistances to ESBL-producing and non-producing E. coli and the rate of ESBL production according to the years were investigated. The results were compared with statistical analysis. Results The rate of ESBL producing E. coli was 21.9% in 2010, and 25% in 2011. There was no resistance to imipenem, meropenem, ertapenem and tigecycline in all strains. The resistance to antibiotics other than amikacin was statistically significant in ESBL producing E. coli compared to ESBL non-producing E.coli (p

Objective: Acinetobacter baumannii is a gram negative, antimicrobial-resistant bacilli difficult to control and treat. This pathogen has became more important in the last decades due to multidrug-resistant nasocomial infections. The aim of this study was to determine the antibiotic resistance rates of A.baumannii isolated from various clinical specimens of intensive care unit (ICU) patients between November 2010 and December 2011. Material and Methods: A total of 172 A.baumannii strains were isolated. Identification and antibiotic susceptibility testing were performed by VITEC 2 (bioMerieux, France) system. Results: A. baumannii strains were isolated 44% from tracheal aspirate, 25% from wounds, 24% from blood, and 7% from urine, consecutively. Although there were no resistant strains detected to colistin and tygecycline, resistance rates of the other antibiotics were found to be 64% for amicacin, 67% for gentamicin, %73 for levosoxacin, 76% for ciprosoxacin, %79 for cefoperazone/sulbactam, 84% for piperacillin/tazobactam, and 92% for imipenem and meropenem, consecutively. Conclusion: In conclusion, no resistant strains were detected to colistin and tygecycline and they were found to be the preferred empirical treatment for A. baumannii infections.